Citations

Clear

2228 citation(s) found for "Le, Anne".

Patient and Caregiver Preferences for Acute Seizure Medications: A Quantitative Survey (P9-11.003)
Laloyaux, Cedric, Villanueva, Vicente, Sirven, Joseph, Jimenez-Moreno, Cecilia, Ho, Kerrie-Anne , Laloyaux, Cédric, Tervonen, Tommi , Villanueva, Vicente , Kukla, Alison , Jimenez‐Moreno, Cecilia

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000213098 Get It

Patient-reported Outcomes Through 12-weeks of Double-blind Rimegepant Treatment for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives (P1-15.008)
Starling, Amaal, Versijpt, Jan, Aslan, Ayşe Neslihan, Seehra, Harpreet, Ramaker, Sara Anne, McCollum, Shannin, Thiry, Alexandra, Abraham, Lucy, Fountaine, Robert, Ramirez, Luz, Versijpt, Jan J. , Sumelahti, Marja‐Liisa , Ramaker, Sara , Thiry, Alexandra, Abraham, Lucy , Fountaine, Robert J.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000212882 Get It

Patient Preferences for Result Communication Across the Breast Imaging Continuum: A Review
Maimone, Santo , Dodelzon, Katerina , Kendell, Anne Elizabeth , Coffey, Kristen , Maimone, Santo , Dodelzon, Katerina , Porembka, Jessica H.

Mayo Clinic

Journal of Breast Imaging | June 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jbi/wbag037 | PMID 42497022 Get It

Abstract Patient preferences for communication of breast imaging results are heterogeneous and depend on the clinical context and perceived severity of findings. The 21st Century Cures Act, which mandates immediate electronic release of most medical records, has fundamentally altered result reporting and patient communication in breast imaging. Although this policy enhances transparency and timely access to information, it may conflict with established preferences for how patients receive screening mammography results, diagnostic evaluations, breast biopsy results, and breast cancer risk assessment information. Prior studies—largely conducted before widespread patient portal use—demonstrated that breast imaging patients consistently prioritize timely communication, while preferred delivery methods vary based on result acuity and emotional impact. However, much of this literature pre-dates implementation of the 21st Century Cures Act and widespread use of patient portals. This review examines the current literature to summarize evidence-based patient preferences for breast imaging result communication. As adoption of immediate result release continues to evolve across institutions, understanding contemporary patient preferences is essential to guiding radiologists in optimizing patient-centered communication strategies to inform best practices in breast imaging.
Clinicopathologic characteristics of early‐onset breast cancer among unselected young Black women
Shah, Tiana, Tinker, Rory J., Weidner, Anne , Venton, Lindsay , Roberson, M., Lehmann, Brian D. , Couch, Fergus J., Reid, Sonya, Metcalfe, Kelly , Pal, Tuya, Tinker, Rory J. , Beasley, Heather K , Weidner, Anne , Venton, Lindsay , Metcalfe, Kelly A , Tinker, R J , Beasley, Heather K. , Hu, Chunling , Roberson, Mya L. , Lehmann, Brian David , Couch, Fergus J. , Pal, Tuya

Mayo Clinic

Cancer | June 8, 2026 | Volume: 132 | Issue: 12 | Pages: No page available

10.1002/cncr.70402 | PMID 42252839 Get It

Abstract Background Black women are more likely to develop and die from early‐onset breast cancer. Hereditary breast cancer (HBC) is strongly associated with early age of onset. Accordingly, HBC characteristics in young Black women were evaluated. Methods Black women diagnosed with invasive breast cancer at age 50 years or younger between 2005 and 2018 were recruited through the state cancer registries in Florida and Tennessee. Participants were asked to complete a questionnaire, sign medical records releases, and donate a saliva sample for free genetic testing to identify HBC germline pathogenic or likely pathogenic variant (GPV). Women with sporadic versus hereditary breast cancer were compared, based on age distribution, clinical characteristics, and family cancer history. Results Among 686 participants with confirmed genetic testing, 15.3% had GPVs in breast and/or ovarian cancer predisposition genes, including BRCA1 (7.7%), BRCA2 (4.5%), PALB2 (0.9%), and ATM (0.7%), with 1.5% in other genes. Compared to the sporadic group, triple‐negative breast cancers were overrepresented among BRCA1 carriers (23.6% vs. 75.5%; p < .001), and family history of breast cancer was significantly more frequent among BRCA1 , BRCA2 , and PALB2 carriers (all p < .05). The majority of breast cancers occurred by age 40 years in BRCA1 carriers (52.8%), compared to other genes, where age was more evenly distributed. Conclusion Among unselected young Black women with breast cancer, our findings demonstrate that the highest frequency of HBC GPVs are in BRCA1 , BRCA2, and PALB2, with identification of distinct histopathologic and demographic characteristics across HBC genes, underscoring the critical need for genetic testing in all populations.
Management of High-Risk Breast Lesions: A Comprehensive Update
Zamora, Kathryn , Vorhis, Elizabeth B, Chikarmane, Sona A. , Coffey, Kristen , Dodelzon, Katerina , Evans, Madeline, Kendell, Anne Elizabeth , Maimone, Santo , Zhou, Wenhui, Bahl, Manisha , Zamora, Kathryn W , Komforti, Miglena K. , Coffey, Kristen , Dodelzon, Katerina , Maimone, Santo , Vorhis, Elizabeth, Porembka, Jessica H.

Mayo Clinic

Journal of Breast Imaging | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jbi/wbag034 | PMID 42490060 Get It

Abstract High-risk breast lesions (HRLs) encompass a heterogeneous group of pathologies that coexist with an adjacent or synchronous malignancy, confer an increased risk of future breast cancer, or warrant surgical consideration because of upgrade potential or local behavior. Despite their clinical importance, management of HRLs remains variable. The American Society of Breast Surgeons (ASBrS) and the Society of Breast Imaging are collaborating to establish unified, evidence-based guidelines for managing these lesions. While these recommendations are currently in development, this review summarizes the existing literature and current guidance, including ASBrS recommendations, to provide context for multidisciplinary management. The article reviews the histopathologic features, imaging appearance, and management strategies for HRLs, including atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), flat epithelial atypia (FEA), papillomas with and without atypia, radial scar/complex sclerosing lesion (RS/CSL), mucocele-like lesion (MLL), desmoid tumor, and pseudoangiomatous stromal hyperplasia (PASH). Recent literature supports nonoperative management for specific radiologic-pathologic concordant lesions, particularly limited ADH, pure FEA, and pure RS, highlighting the important role of multidisciplinary discussion for personalized care. Lesions such as LCIS subtypes, papilloma with atypia, and MLL with atypia continue to warrant excision due to higher reported upgrade rates to malignancy. Beyond short-term management, HRLs such as ADH, ALH, and LCIS serve as biomarkers of long-term breast cancer risk, informing recommendations for surveillance, risk assessment, and chemoprevention counseling. Achieving a consensus among radiology, pathology, and surgical disciplines is essential to ensure oncologic safety while minimizing overtreatment in the era of precision breast care.
Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial.
O'Sullivan, Ciara Catherine, Kalinsky, Kevin, Yau, C, Wallace, Anne M., Chien, Jo, Yee, D, Nanda, Rita, Isaacs, C, Omene, Coral, Kulkarni, T, Swigart, Lamorna Brown, Perlmutter, J, Hylton, N, Borowsky, Alexander D., Rugo, H S, Veer, Laura van't, Esserman, L J, O’Sullivan, Ciara C. , Kalinsky, Kevin M. , Yau, Christina , Yee, Douglas , Boughey, Judy C. , Borges, Virginia F. , Isaacs, Claudine , Omene, Coral , Kulkarni, Tejaswini , Swigart, Lamorna Brown , Hylton, Nola, Shatsky, Rebecca , Veer, Laura J. van’t

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba514 Get It

LBA514 Background: Preclinical and clinical data show that antibody-drug conjugates (ADCs) such as T-DXd may synergize with immunotherapy. Rilvegostomig (R) is a monovalent, Fc-reduced, dual checkpoint bispecific IgG1 monoclonal antibody against PD-1 and TIGIT receptors. R + T-DXd was evaluated as neoadjuvant therapy for up to 4 cycles. Methods: I-SPY2.2 is a phase II neoadjuvant trial with three neoadjuvant sequences (Blocks A/B/C). All HER2-negative subtypes were eligible for R + T-DXd in Block A. Predicted responders at the end of Block A or B could undergo surgery; otherwise, they continued to Block B +/- C. Block B pts received paclitaxel +/- carboplatin +/- pembrolizumab and Block C pts doxorubicin + cyclophosphamide (AC) +/- pembrolizumab, HR+ immune+ received IO in Blocks B/C. Results are analyzed by receptor and response predictive subtypes (RPS), that include expression-based immune, and luminal signatures with hormone receptor (HR) and HER2 status. Some pts were randomized to a control regimen (skipping R + T-DXd in block A and starting in block B). To minimize risk of interstitial lung disease (ILD) that could lead to treatment discontinuation, pts underwent pulmonary function tests and high-resolution chest CTs every 6 weeks. Abnormalities were reviewed in real time. The primary endpoint was pathologic complete response (pCR), within each RPS and HR/HER2 signature, with estimated pCR (EpCR) rates compared to subtype-specific block A goal rates and control pts in those groups. Other endpoints included safety and treatment discontinuation. Results: 105 pts were treated with R + T-DXd in block A, while 31 pts were randomized to the control regimen. Block A EpCR rate was 57% in the 12 HR+Immune+ pts vs a pre-specified goal of 15% (posterior probability, PP > .99). In 35 HR-Immune+ pts EpCR was 52% vs a pre-specified goal of 40% (PP = .87). No other groups (Immune-) had a PP > .85 for their respective pCR goal rate. HER2-IHC was 0 (27.6%), 1+ (49.5%) and 2+ (22.9%) in the treatment arm vs. 37.7%, 37.7%, and 24.7% in the control arm, with no difference in distribution between arms in immune subtypes. The most common adverse events in Block A were fatigue (84.8%), nausea (81.0%) and alopecia (58.1%). ILD was the most common adverse event of special interest in Block A and overall, occurring in 12 pts (11.4%; 7G1, 4G2, 1G3) during Block A and in 3 pts (G1, 2.9%) in other Blocks. 8 pts discontinued T-DXd + R due to ILD and proceeded to the next Block. Conclusions: When considering the full treatment strategy including block B and C regimens, experimental strategies had similar EpCR rates vs. controls in immune+ subtypes but block A rates exceeded pre-defined goal thresholds. This infers that treatment beginning with R + T-DXd has equivalent efficacy to standard of care for immune+ pts, but 64% pts with pCR skip chemotherapy (Block B) and 97% avoid AC (Block C). R + T-DXd participants avoided persistent ILD. Clinical trial information: NCT01042379 .
Treatment burden and health‐related quality of life in young adults with type 1 diabetes
Gastel, Anka Van, Graner‐Baars, Matthijs, Stiggelbout, Anne M., Tran, Viet‐Thi, Mesman, Jessica, Swaak, Joris, Aanstoot, Henk‐Jan, Kunneman, Marleen , Mesman, Jessica , Van Gastel, Anka , Dinneen, Sean F , De Koning, Eelco J P , Kunneman, Marleen , Graner, Matthijs, Stiggelbout, Anne, Tran, Viet-Thi , Giltay, Erik J. , Dinneen, Seán F. , Aanstoot, Henk‐Jan , Montori, Víctor M.

Mayo Clinic

Diabetic Medicine | June 3, 2026 | Volume: 43 | Issue: 8 | Pages: No page available

10.1111/dme.70376 | PMID 42233704 Get It

Abstract Aim This study aims to assess the treatment burden and health‐related quality of life (HRQoL) in young adults with type 1 diabetes (T1D). Methods Online survey on experienced treatment burden (Treatment Burden Questionnaire, TBQ, 0–150, higher scores indicate higher burden) and HRQoL (Type 1 Diabetes and Life questionnaire for ages 18–25 and 26–45, T1DAL, 0–100, higher scores indicate better HRQoL) among Dutch young adults with T1D (aged 18–30). Results In total, 294 young adults with T1D completed the survey. Mean TBQ score was 59.5 (SD = 24.9). Regular medical care reminding participants of their health problems scored highest. Mean T1DAL scores were 55.9 (SD = 12.9) for ages 18–25, and 62.1 (SD = 13.2) for ages 26–30. Lowest scores were in the subcategory ‘Emotional experiences and daily activities’ (18–25: median = 41.7, IQR = 24.9; 26–30: median = 47.8, IQR = 22.5). TBQ was strongly negatively correlated with T1DAL ( r = −0.69, 95% CI [−0.74, −0.62], p < 0.001). Characteristics associated with higher treatment burden and lower HRQoL included female gender, lower time in range and dissatisfaction with diabetes management approach. Conclusion Young adults with T1D report considerable treatment burden and moderate HRQoL, suggesting a high impact of diabetes care on their lives. Treatment burden is particularly affected by regular medical care activities, whereas diabetes affects the daily functioning and emotional experiences domains of HRQoL. Further research is needed to understand how young adults make care fit and to improve care for these patients, resulting in minimally disruptive care plans. While cautiously interpreted, this may be especially relevant for women and those with adverse clinical outcomes.
Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities
Laule, Cornelia , Cohen-Adad, Julien, Witt, Atlee , Luca, Gabriele C. De, Granziera, Cristina , Keegan, B. Mark , Kerbrat, Anne , Klawiter, Eric C, Kolind, Shannon , O’Grady, Kristin P. , Oh, Jiwon, Sivakolundu, Dinesh K. , Smith, Seth A, Vavasour, Irene M, Mainero, Caterina , Alonso-Ortiz, Eva, Krieger, Stephen , Li, David , Shinohara, Russell T, Henry, Roland G, Cooperative, North American Imaging in Multiple Sclerosis (NAIMS), Witt, Atlee A , De Luca, Gabriele C , Bagnato, Francesca R. , Gauthier, Susan A , Bakshi, Rohit , Beck, Erin S , Krieger, Stephen , Keegan, B Mark , Kollind, Shannon H , Granziera, Cristina , O'Grady, Kristin P , Cohen-Adad, Julien , DeLuca, Gabriele C. , Kerbrat, Anne , Klawiter, Eric C. , Oh, Jiwon , Schilling, Kurt G. , Smith, Seth A. , Tozlu, Ceren , Vavasour, Irene M. , Alonso‐Ortiz, Eva , Brier, Matthew R. , Hemond, Christopher C , Li, David K.B. , Shinohara, Russell Taki , Henry, Roland G.

Mayo Clinic

Multiple Sclerosis Journal | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13524585261444600 | PMID 42224274 Get It

The spinal cord plays a central role in the pathophysiology and clinical manifestations of multiple sclerosis (MS), yet remains under-studied compared with the brain. This review summarizes key insights from the 2025 North American Imaging in MS Spinal Cord Imaging Workshop, highlighting recent advances, ongoing challenges, and future opportunities in MS spinal cord imaging. We review pathological studies and outline the clinical relevance of spinal cord lesions and atrophy for diagnosis, prognosis, and disease monitoring, highlighting emerging biomarkers of progression independent of relapse activity. Correlations between magnetic resonance imaging, histopathology, and clinical outcomes support the validation and translational potential of advanced spinal cord imaging techniques. Finally, we discuss spinal cord–specific processing pipelines and reproducibility challenges. Collectively, these insights underscore the need to integrate advanced and quantitative spinal cord imaging into clinical trials, research studies, and—when feasible—clinical care, to fully capture the extent of MS pathology, and ultimately improve patient outcomes.